Comments
Laurus Labs Ltd has completed the US Food and Drug Administration (USFDA) inspection of its Unit – 2 (FDF&API integrated facility), located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh with two observations.
“The observations are in procedural in nature,’’ the Hyderabad-based Laurus said in a release.
This was a product pre-approval audit by USFDA, and no data integrity issues were observed in the inspection. The inspection was carried out from November 4-8, the company said.
Laurus Labs scrip lost 0.78 per cent to end at ₹366.90 on the BSE on Friday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.